Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees ...

CNBC's Silvia Amaro takes a look at the rise and fall in Novo Nordisk shares.

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

The investment conglomerate reported a higher-than-expected profit, aided by a recovery in its te ...

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Novo Nordisk A/S (NYSE:NVO) is among the. Novo Nordisk A/S (NYSE:NVO) lowered its operating profit growth projections to ...

A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict ...

Novo Nordisk has a commercial relationship with Economist Impact, a division of The Economist Group. The Economist operates ...